Adoptive Cell Therapies Offer ‘New Hope’ for Patients With Limited Treatment Options
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid tumor treatment.
Certain characteristics seen in solid tumors — such as antigenic heterogeneity and the immunosuppressive tumor microenvironment — have dampened the efficacy of antigen-directed therapies for these patients, leading to the emergence of other adoptive cell therapies for solid tumors, such as tumor-infiltrating lymphocytes (TIL) and genetically engineered T-cell receptors (TCR).